Dabur Pharma Ltd. India’s leading oncology player, today announced that the Drug Controller General of India (DCGI) has approved its proprietary Nanoparticle Paclitaxel formulation “NANOXEL” for additional indications of Ovarian Cancer, Non-small Cell Lung Cancer and AIDS related Kaposis’s Sarcoma.
NANOXEL had earlier been approved by the DCGI in 2006 for the treatment of Breast Cancer and after its launch in January 2007, hundreds of patients have benefited from this novel formulation.
Speaking on the occasion Mr. Ajay Kumar Vij, CEO, Dabur Pharma Ltd. said, “We are very pleased by DCGI’s decision. Consistent with our mission of making cancer therapy available to more people, this approval will help a much larger patient population have access to a significantly safer and more convenient therapeutic alternative to conventional Paclitaxel”
No comments:
Post a Comment